InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focused on anti-inflammatory therapies targeting the complement system, announced the pricing of its public offering. The offering includes 8,250,000 ordinary shares priced at $2.00 per share, and pre-funded warrants to purchase up to 6,750,000 ordinary shares. The pre-funded warrants will be sold at $1.999 each. InflaRx will sell all shares and warrants. The offering is expected to close February 18, 2025, pending customary closing conditions.

Underwriters have a 30-day option to purchase up to an additional 2,250,000 ordinary shares at the public offering price, less the underwriting discount.

Net proceeds will primarily fund clinical development of vilobelimab and INF904, and for general corporate purposes. 

Guggenheim Securities, LLC serves as book-running manager. H.C. Wainwright & Co. and Lucid Capital Markets, LLC are co-lead managers.

The SEC declared effective a shelf registration statement for the shares and warrants on July 11, 2023. The offering will be made via a prospectus and prospectus supplement, available on the SEC website (www.sec.gov) and from Guggenheim Securities, LLC (details provided in the text).

This press release does not constitute an offer to sell or solicitation of an offer to buy securities where prohibited by law.

About InflaRx N.V.:

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company developing anti-inflammatory therapies using proprietary anti-C5a and anti-C5aR technologies. The company’s lead product candidate, vilobelimab, is an intravenously administered anti-C5a monoclonal antibody. They are also developing INF904, an oral C5a receptor inhibitor. Founded in 2007, InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA. For more information, visit www.inflarx.com.

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals, Inc. (USA) are wholly owned subsidiaries of InflaRx N.V.

Contacts:

InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de 

MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280

US: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Such statements are subject to risks and uncertainties, as detailed in InflaRx’s SEC filings. These statements reflect current views and the company assumes no obligation to update them.